Erbitux Companion Test Approval Clears Path For Further R&D Alliances
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic drug/diagnostic markers show further room for co-development, as demonstrated by the pairing of the colorectal cancer drug Erbitux and DakoCytomation's EGFR pharmDx. ImClone drug reimbursement trends likely will drive uptake of the diagnostic.